You just read:

Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

News provided by

Innovent Biologics, Inc.

Dec 01, 2019, 19:00 ET